Fennec Pharmaceuticals Inc. 8-K Filing

FAQ

Key Financial Figures

• $7.50 — o be sold at a public offering price of $7.50 per share, and will be purchased by the
• $6.975 — rwriters from the Company at a price of $6.975 per Share. The Company also granted the

Filing Documents

• tm2531308d1_8k.htm (8-K) — 33KB
• tm2531308d1_ex1-1.htm (EX-1.1) — 274KB
• tm2531308d1_ex5-1.htm (EX-5.1) — 9KB
• tm2531308d1_ex99-1.htm (EX-99.1) — 12KB
• tm2531308d1_ex99-2.htm (EX-99.2) — 14KB
• tm2531308d1_ex5-1img001.jpg (GRAPHIC) — 10KB
• tm2531308d1_ex99-1img001.jpg (GRAPHIC) — 7KB
• tm2531308d1_ex99-2img001.jpg (GRAPHIC) — 7KB
• 0001104659-25-112912.txt ( ) — 620KB
• fencf-20251113.xsd (EX-101.SCH) — 3KB
• fencf-20251113_lab.xml (EX-101.LAB) — 33KB
• fencf-20251113_pre.xml (EX-101.PRE) — 22KB
• tm2531308d1_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. On November 13, 2025, Fennec Pharmaceuticals Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), pursuant to which the Company agreed to issue and sell an aggregate of 4,666,667 common shares, no par value (the "Shares"), to the Underwriters (the "Offering"). The Shares are to be sold at a public offering price of $7.50 per share, and will be purchased by the Underwriters from the Company at a price of $6.975 per Share. The Company also granted the Underwriters a 30-day option to purchase up to an additional 700,000 Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on November 17, 2025, subject to the satisfaction of customary closing conditions. The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-275452 ), which was previously filed with the Securities Exchange Commission on November 9, 2023 and declared effective on December 15, 2023. A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriters. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to the Underwriting Agreement. The foregoing descriptions of the Underwriting Agreement do not purport to be complete and are qualified in th

01

Item 8.01 Other Events. The full text of the press release announcing the proposed underwritten public offering on November 13, 2025 and the full text of the press release announcing the pricing of the underwritten public offering on November 13, 2025 are attached as Exhibits 99.1 and 99.2 hereto and are incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 1.1 Underwriting Agreement, dated November 13, 2025 , by and among the Company and Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein Exhibit 5.1 Opinion of LaBarge Weinstein LLP Exhibit 23.1 Consent of LaBarge Weinstein LLP (included in Exhibit 5.1) Exhibit 99.1 Press Release dated November 13, 2025 Exhibit 99.2 Press Release dated November 13, 2025 Exhibit 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date: November 17, 2025 By: /s/ Jeff Hackman Jeff Hackman Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR